Liminatus Pharma Amends InnocsAI Merger, $320M Deal to Close Early with Preferred Stock
LIMN sits 65% above its 52-week low of $0.095.
Summary
Liminatus Pharma has amended its definitive merger agreement with InnocsAI, allowing the $320 million implied transaction to close on July 2, 2026, prior to full stockholder approval. The new structure involves issuing common stock (up to 19.99%) and non-voting convertible preferred stock for the balance of the consideration. This move enables Liminatus to quickly integrate InnocsAI's oncology pipeline, a critical strategic step for the company which recently announced a reverse stock split proposal and faces Nasdaq delisting. While accelerating the merger, the deal introduces a complex equity structure with significant future dilution once the preferred shares are approved for conversion. An 8-K filing with further details is expected.
At the time of this announcement, LIMN was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.10 to $12.90. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.